Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy
Authors
Keywords
-
Journal
Artificial Cells Nanomedicine and Biotechnology
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2018-07-11
DOI
10.1080/21691401.2018.1481863
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
- (2017) Maya Sreeranganathan et al. International Journal of Nanomedicine
- Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody
- (2017) Saeideh Abdolahpour et al. Artificial Cells Nanomedicine and Biotechnology
- An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
- (2017) Md. Habban Akhter et al. Current Drug Delivery
- Global temporal patterns of pancreatic cancer and association with socioeconomic development
- (2017) Martin C. S. Wong et al. Scientific Reports
- EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery
- (2016) Azadeh Haeri et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Immunotherapy for small-cell lung cancer: emerging evidence
- (2016) Martin Reck et al. Future Oncology
- FGFR Signaling as a Target for Lung Cancer Therapy
- (2016) Arpita Desai et al. Journal of Thoracic Oncology
- Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors
- (2016) Ana P. S. Silva et al. Human Vaccines & Immunotherapeutics
- Magnetic nanoparticles in cancer diagnosis and treatment: a review
- (2016) Sonia Fathi Karkan et al. Artificial Cells Nanomedicine and Biotechnology
- Computational approaches in target identification and drug discovery
- (2016) Theodora Katsila et al. Computational and Structural Biotechnology Journal
- Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma
- (2016) Martin J. Hicks et al. PLoS One
- Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance
- (2016) Yuetong Wang et al. Scientific Reports
- EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer
- (2015) Goutam Mondal et al. BIOMACROMOLECULES
- Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial
- (2015) Andreas Wicki et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells
- (2015) Yanuar Dwi Putra Limasale et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
- (2015) Ismael Riquelme et al. Oncotarget
- Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
- (2015) Meena Jhanwar-Uniyal et al. Cancers
- A cisplatin-incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity
- (2014) JOOHEE JUNG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells
- (2013) Ravendra Singh et al. JOURNAL OF DRUG TARGETING
- Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model
- (2013) Nour Karra et al. Small
- Targeting HER Receptors in Cancer
- (2012) Alberto Ocana et al. CURRENT PHARMACEUTICAL DESIGN
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
- (2012) T. R. Fenton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1
- (2012) Serena L. Clark et al. Computational and Structural Biotechnology Journal
- Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
- (2011) Laetitia Dahan et al. BMC CANCER
- Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
- (2011) Matias E. Valsecchi et al. CANCER
- Nanoparticle delivery of a peptide targeting EGFR signaling
- (2011) Sang Kyoon Kim et al. JOURNAL OF CONTROLLED RELEASE
- Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
- (2011) Lara Milane et al. PLoS One
- Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice
- (2010) Ashwin A Bhirde et al. Nanomedicine
- Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
- (2010) Curtis A Thorne et al. Nature Chemical Biology
- Polyethyleneimine-grafted poly(N-3-hydroxypropyl)aspartamide as a biodegradable gene vector for efficient gene transfection
- (2010) Dan Chen et al. Soft Matter
- Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells
- (2009) A. Cirstoiu-Hapca et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice
- (2009) In-Young Kim et al. JOURNAL OF CONTROLLED RELEASE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started